Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Pierre Fabre Group
Headquarters: Castres, France
Website: http://www.pierre-fabre.com/fr...
Year Founded: 1961
Status: Private
BioCentury | Mar 17, 2025
Deals
AZ acquires cell therapy play Esobiotech, Taiho acquires ADC partner Araris: Deals Report
Plus: Roche partners with Zealand, AZ with Alteogen and more
BioCentury | Jan 8, 2025
Data Byte
Seven PDUFA dates on FDA’s January agenda
Decisions include Ozempic for CKD, a non-opioid painkiller, AZ-Daiichi’s TROP2 ADC, and an allogeneic T cell therapy
BioCentury | Jul 27, 2024
Data Byte
Junshi’s PD-1 among seven new products recommended by EMA’s CHMP
Plus: Astellas’ Vyloy on track to become EU’s first CLDN18.2 therapy, and 11 products likely headed for label expansions
BioCentury | Apr 30, 2024
Data Byte
EMA’s CHMP recommends Takeda VEGF therapy, Idorsia hypertension drug
April opinions also include earlier-line use of J&J’s Rybrevant and BMS’s Opdivo
BioCentury | Nov 20, 2023
Data Byte
FDA, EMA make similar decisions on cell and gene therapies
EMA has grant more expedited approvals than FDA, but regional differences in available therapies mostly due to where the candidates were submitted
BioCentury | Oct 17, 2023
Management Tracks
Allogene named Geoffrey Parker as CFO
Plus: Summit hires Manmeet Soni as COO, and updates from SwanBio, DBV, Lyra and EyePoint
BioCentury | Sep 20, 2023
Deals
Sept. 20 Quick Takes: Orionis, Genentech in molecular glue deal
Plus: Roche gets into radiopharma via PeptiDream deal and updates from Menarini, Merck KGaA, Tolremo, Merck & Co., ARS, Genevoyager
BioCentury | Apr 4, 2023
Deals
April 4 Quick Takes: Scorpion, Pierre Fabre enter deal for pair of EGFRs
Plus: EUA for InflaRx’s antibody for COVID-19 and updates from Adcendo, Mercy, Mosaic, Freeline and Gossamer
BioCentury | Aug 15, 2022
Product Development
Viridian’s ‘fast follower’ could challenge Tepezza in thyroid eye disease
Biotech maps out Phase III strategy for therapy it believes could be best in class, rivaling Horizon’s strong-selling, first-to-market drug
BioCentury | Aug 19, 2021
Product Development
Dealmaking and bispecifics cut trail to IPO for Y-Biologics
Korea Spotlight: Y-Biologics’ in-house antibody technology key to series of global partnerships
Items per page:
1 - 10 of 60